Answers are grounded in this paper and cite their sources.
Intravenous phage therapy enables systemic bacteriophage delivery in difficult-to-treat infections, but raises distinct pharmacokinetic, immunological and safety considerations, while evidence remains fragmented. Here in this systematic review we analysed 60 studies from nine high-income countries, predominantly case reports, case series and uncontrolled trials reporting intravenous phage therapy with or without local administration and mostly alongside antibiotics. We extracted and synthesised individual patient data both descriptively and through a meta-analysis using mixed-effects models, which estimated probabilities of reporting clinical improvement and microbiological eradication of 65.8% (n = 122) and 55.3% (n = 106), respectively, while the probability of reporting adverse reactions was 9.2% (n = 168), with reactions predominantly mild and self-limited. In exploratory analyses, combined intravenous and local administration was associated with more frequent reporting of clinical improvement than intravenous administration alone, raising questions regarding potential limitations of the intravenous route. However, the uncontrolled and heterogeneous nature of current evidence warrants cautious interpretation and underscores the need for rigorous research.
No takes yet. Share an insight, caveat, or question.
Guerrero et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: